NCT01535066 is a NA clinical trial of acupuncture therapy in Breast Cancer, sponsored by SWOG Cancer Research Network.

Who is sponsoring NCT01535066?

NCT01535066 is sponsored by SWOG Cancer Research Network.

What drugs are being tested in NCT01535066?

Interventions in NCT01535066: acupuncture therapy, sham acupuncture.

What condition does NCT01535066 study?

NCT01535066 studies Breast Cancer, Pain.

Is NCT01535066 still recruiting?

NCT01535066 is currently completed. Last updated 7 December 2022.

Last reviewed 2022-12-07 · How we verify

NCT01535066

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer

Completed NA Last updated 7 December 2022

What this trial tests

NA trial testing acupuncture therapy in Breast Cancer in 226 participants. Completed in 1 July 2018.

Timeline

16 May 2012

Primary endpoint
15 June 2017

1 July 2018

Quick facts

Lead sponsor	SWOG Cancer Research Network
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	single
Primary purpose	supportive care
Enrollment	226
Start date	16 May 2012
Primary completion	15 June 2017
Estimated completion	1 July 2018
Sites	47 locations across United States

Drugs / interventions tested

acupuncture therapy
sham acupuncture

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Pain — all drugs for Pain →

Sponsor

SWOG Cancer Research Network

Who can join

18 and older, female only, with Breast Cancer or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Acupuncture may help relieve joint pain. PURPOSE: This randomized phase III trial studies acupuncture to see how well it works compared to sham acupuncture or waitlist in treating patients with joint pain related to aromatase inhibitors in patients with early-stage breast cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
Hershman DL, Unger JM, Greenlee H, Capodice JL, et al · · 2018 · cited 219× · PMID 29998338 · DOI 10.1001/jama.2018.8907
A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
Bao T, Cai L, Giles JT, Gould J, et al · · 2013 · cited 63× · PMID 23393007 · DOI 10.1007/s10549-013-2427-z
Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial.
Hershman DL, Unger JM, Greenlee H, Capodice J, et al · · 2022 · cited 39× · PMID 36367721 · DOI 10.1001/jamanetworkopen.2022.41720

Verify or expand the search:

Other trials of acupuncture therapy

Trials testing the same drug.

NCT05240586 — Pharmacopuncture Therapy for Cervical Disc Herniation: A Pilot Study · NA · completed

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other SWOG Cancer Research Network trials

Trials by the same sponsor.

NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07278739 — Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams · NA · not yet recruiting
NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
NCT07018869 — Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01535066 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SWOG Cancer Research Network
Last refreshed: 7 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01535066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing